Suven granted patents for its neurodegenerative drug

The patents by South Korea and China are valid till 2029 while that by Canada is valid till 2030

South Korea, Canada and China, have individually granted Suven lifesciences, product patents for its neurodegenerative drug.

The patents approved by South Korea and China are valid till 2029 while that by Canada is valid till 2030.

"A product patent from South Korea, one from China and another from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases," the company said in a BSE filing.

"We are very pleased by the grant of these patents to Suven, for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need and with huge market potential globally," said company's CEO Mr Venkat Jasti.